Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity

<div>(a) AP-ROP prior to the bevacizumab injection: male infant, BW 1000 g, GA 28 w, treated with intravitreal bevacizumab at PMA of 34 weeks and PNA of 6 weeks. (b) Fundus photography 5 days after bevacizumab injection with venous dilatation and arteriolar tortuosity improvement in the posterior pole, showing plus disease regression.</div>

Journal of Ophthalmology

fig1

Figure 1

Figure 1: Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity 

Figure 1 | Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity 